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Abstract 
To assess and validate the incorporation of the multiparametric magnetic resonance imaging (mpMRI) tumour cat‑
egory (mT‑category) to the conventional clinical tumour category (cT‑category), in order to guide the radiotherapy 
(RT) treatment decisions in prostate cancer. In addition, to identify the clinical factors associated to the technique 
reliability. mpMRI was performed in 274 prostate cancer patients in order to refine the treatment decisions according 
to PSA, Gleason Score (GS) and cT‑category. Comparisons between the cT and mT‑category were performed, as well 
as the impact on the RT treatment [target volume, doses and hormonal therapy (HT)] independently if it was finally 
performed. Changes in HT indication for intermediate risk were also analyzed. mpMRI validation was performed with 
pathological staging (n = 90 patients finally decided to join surgery). The mpMRI upstaging range was 86–94 % for 
any PSA value or GS. Following mpMRI, 32.8 % of the patients (90/274) were assigned to a different risk group. Com‑
pared to cT‑category, mpMRI identified more intermediate‑risk (46.4 vs. 59.5 %) and high‑risk (19.0 vs. 28.8 %) prostate 
cancer patients. This resulted in a higher indication (p < 0.05) of seminal vesicle irradiation (63.5 vs. 70.0 %), inclu‑
sion of any extracapsular disease (T3–T4) within the target volume (1.8 vs. 18.2 %), higher doses (65.3 vs. 88.3 %) and 
HT associated to RT (45.6 vs. 62.4 %). Global accuracy for mpMRI was higher compared to DRE/TRUS (8.9 vs. 71.1 %, 
p < 0.05). mpMRI reliability was independent of PSA or GS. mpMRI tumor staging significantly modified the RT treat‑
ment decisions in all prostate cancer risk groups.
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Background
Clinical tumoural category (cT-category) is a determin-
ing factor in prostate cancer management. Thus, cT-cate-
gory, along with prostate-specific antigen level (PSA) and 
Gleason score (GS), contribute to establishing tumour 
recurrence risk groups, and subsequently to making radi-
otherapy treatment (RT) decisions [such as target vol-
ume, total dose, and addition of hormonal therapy (HT)]. 
In determining the cT-category in prostate cancer, digi-
tal rectal examination (DRE) and transrectal ultrasound 
(TRUS) remain the gold-standard methods recom-
mended in almost all guidelines and protocols (Mohler 
et al. 2014; Heidenreich et al. 2014). However, both tests 
have very low reliability and high interobserver variability 
(Philip et al. 2005; Smith and Catalona 1995). This could 
result in erroneous estimation of the cT-category, poten-
tially resulting in inappropriate treatment, particularly in 
relation to RT.
In recent years, multiparametric magnetic resonance 
imaging (mpMRI) has been the most reliable technique 
for local tumour staging in prostate cancer patients, com-
pared with conventional tests such as DRE, TRUS and 
morphological MRI, as well as predictive tools such as 
the Partin tables and the Kattan nomogram (Hricak et al. 
1987; Mullerad et  al. 2005; Augustin et  al. 2009; Wang 
et  al. 2007). However, few studies have focused on the 
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impact of mpMRI staging in relation to RT target vol-
umes, total dose administered, or the use of HT (Cou-
ñago et al. 2014; Panje et al. 2015).
Although heterogeneity is common among institu-
tional protocols (Horsley et  al. 2015), at our institution, 
the recommendation for low-risk patients is to treat the 
prostate with RT (76–78 Gy) without associated HT; by 
contrast, for organ-confined (T1–T2) intermediate-risk 
and high-risk patients, the irradiation of both prostate 
and seminal vesicles (78–80  Gy) is indicated (Mohler 
et al. 2014; Heidenreich et al. 2014). In high-risk patients 
with locally advanced disease (T3–T4), it is also neces-
sary to extend the target volume beyond the prostatic 
capsule to encompass any type of extracapsular exten-
sion (ECE) (Boehmer et  al. 2006; Hayden et  al. 2010). 
Long-term HT treatment (≥24  m) is recommended for 
high-risk patients. Short-term treatment (4–6  m), while 
controversial, is recommended for intermediate-risk 
patients with unfavourable prognostic factors (Zapatero 
et  al. 2015; D’Amico 2015). Either prophylactic lymph 
node irradiation or brachytherapy boost following RT 
are optional in intermediate-risk and high-risk patients 
(Mohler et al. 2014; Heidenreich et al. 2014).
With this in mind, the principal aim of our study was 
to analyse and validate the consequences of mpMRI stag-
ing for RT treatment decisions (target volume, doses and 
HT) in prostate cancer, as well as to determine the clini-
cal factors associated with mpMRI reliability.
Methods
Study design
This is a retrospective study conducted in our Oncol-
ogy Department with the approval of Quiron Hospi-
tal’s Ethics Committee. Between January 2009 and April 
2015, 274 patients with histological diagnoses of primary 
prostate cancer, mpMRI-categorized and considered for 
definitive treatment with RT ± HT or radical prostatec-
tomy (RP), were included in our study. Patients without 
mpMRI staging prior to any treatment (n = 175) or with 
non-assessed mpMRI due to bleeding after prostatic 
biopsy (n =  6) were excluded. Ten patients without cT-
category were also excluded. All patients were assessed 
by Urology and Radiation Oncology Services before the 
definitive treatment decision. The completion of RT 
treatment was not essential for inclusion in the study, as 
decisions regarding target volume, doses, and HT depend 
exclusively on tumour category, PSA value and GS.
Before treatment was started, patients’ baseline charac-
teristics were evaluated, including age at diagnosis, DRE, 
PSA value at diagnosis, and a TRUS-guided biopsy from 
which the patients’ GS were obtained. Other imaging 
techniques (CT and bone scan) were optional, accord-
ing to international guidelines (Mohler et  al. 2014; 
Heidenreich et  al. 2014) and the physician’s judgment, 
basically in intermediate and high risk patients. cT-cat-
egory before mpMRI was assigned on the basis of DRE 
and TRUS. Tumour category was assessed according to 
the American Joint Committee on Cancer (AJCC) sys-
tem, 7th edition (AJCC 2010). Based on PSA values, GS 
and cT-category, relapse risk groups were established 
following the National Comprehensive Cancer Net-
work guidelines version 2.2014: low-risk, ≤T2a, GS ≤ 6 
and pretreatment PSA  <10  ng/mL; intermediate-risk, 
T2b–T2c or GS  =  7 or PSA 10–20  ng/mL; high-risk, 
T3–T4 or GS >7 or PSA >20 ng/mL; metastatic, N+ or 
M+ (Mohler et al. 2014).
Based on the prostate cancer clinical protocol in force 
in our institution’s radiotherapy unit, initial indication 
(target volume, doses and HT) was established according 
to cT-category; ultimate indications were based on MRI 
tumour category (mT-category). Up- or downstaging, 
changes in risk group, and alterations in RT treatment 
due to tumour category variations were analysed. In 
addition, for patients whose final treatment consisted of 
RP (n = 90), the mT-category was compared to the path-
ologic tumour category (pT-category), which allowed us 
to validate mpMRI results.
mpMRI technique
mpMRI was performed on an eight-channel torso-array 
antenna 3 Tesla (General Electric, USA) in previously 
prepared patients. The study protocol was extensively 
described in a previous study (Couñago et  al. 2014). 
In brief, morphological imaging included T1- and 
T2-weighted sequences and functional studies included 
diffusion-weighted imaging (DWI) and dynamic con-
trast-enhanced (DCE) imaging. The apparent diffusion 
coefficient (ADC) map was calculated while using DWI. 
DCE imaging was performed applying contrast with gad-
olinium. In the DCE study, time-intensity curves were 
calculated. The mpMRI was performed after conven-
tional clinical staging, and always interpreted by one uro-
radiologist experienced in pelvic MRI.
Risk‑adapted RT
Patients underwent treatment in a multienergetic lin-
eal accelerator with intensity modulated radiotherapy 
(IMRT). In low-risk patients, the dose was 76–78  Gy, 
increasing to 78–80  Gy in intermediate-risk and high-
risk patients. The clinical target volume (CTV) included 
only the prostate in low-risk patients, while the prostate 
and seminal vesicles were included in intermediate-risk 
and high-risk patients. CTV was extended to include 
ECE in T3–T4 patients, following the recommenda-
tions of clinical guidelines (Boehmer et al. 2006; Hayden 
et al. 2010). The pelvis was not included, except in cases 
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with clinical pelvic node involvement. High-risk patients 
received long-term HT (2–3 years) and intermediate-risk 
patients with unfavourable factors received short-term 
HT (4–6  months). Until 2014, the unfavourable factors 
according to the initial criteria were a GS of 7 (4 + 3), or 
three unfavourable intermediate risk factors (T2b + PSA 
10–20 ng/mL + GS 3 + 4), or T2c by DRE/TRUS; more 
recently, unfavourable risk factors have been established 
according to memorial sloan kettering cancer center 
(MSKCC) criteria: GS 4 + 3, or at least two intermediate-
risk factors, or at least one intermediate-risk factor and a 
positive prostate biopsies (ppb) percentage greater than 
50 % (D’Amico 2015; Zumsteg et al. 2013).
Statistical analysis
The data analysis was performed with IBM SPSS statistics 
version 21.0 (IBM Corp; USA). Descriptive statistics are 
reported as median (IQR, interquartile range) or mean 
(SD, Standard Deviation) for continuous variables, and as 
absolute or relative frequencies for categorical variables. 
Patient basal characteristics and the differences in treat-
ment impact on DRE/TRUS vs. mpMRI, as well as the 
reliability of the diagnostic tests, were compared using 
the Chi square test and Fisher’s exact test, both for cat-
egorical variables. The U Mann–Whitney test was used 
for the non-parametric quantitative variables. To analyse 
the relationship between the reliability of mpMRI and the 
clinical variables, a univariate and multivariate logistic 
regression analysis was performed.
Results
The baseline patient characteristics of the entire cohort 
(n  =  274) and the surgical patient cohort (n  =  90) are 
summarised in Table 1. Upstaging occurred in 90.9 % of 
the patients (249/274 patients; see Fig. 1). The upstaging 
range was 86.1–94.2 % for any PSA or GS value. Down-
staging was not observed. Following mpMRI, 32.8  % of 
the patients (90/274) were assigned to a different risk 
group. Finally, decisions concerning RT were changed 
in 43.8 % (initial criteria) or 52.5 % (MSKCC criteria) of 
the patients, depending on the criteria applied to indicate 
HT in intermediate-risk patients.
Upstaging from cT1–T2a to mT2b-T2c occurred in 137 
patients of a total of 239 patients (57.3 %). 58 out of 239 
patients (24.2 %) upward shift from low-risk to interme-
diate-risk resulting in a modification of target volume 
due to the inclusion of seminal vesicles, and the increase 
in dosage from 76–78 to 78–80 Gy. In 7 of a total of 11 of 
the intermediate-risk patients (cT1–cT2a and GS 3 +  4 
and PSA 10–20  ng/mL), short-term HT was also indi-
cated, as 3 unfavorable risk factors were present. How-
ever, if the most recent MSKCC criteria had been applied, 
31 out of 41 intermediate-risk patients [cT1–cT2a and 
(GS 3 +  4 or PSA 10–20 ng/mL or ppb >50 %)], would 
have received short-term HT.
Among the 269 cT1–T2 patients, 45 (16.7  %) pro-
gressed to mT3–T4, based on the detection of any type 
of ECE in mpMRI. This entailed an alteration of target 
volume due to the inclusion of seminal vesicles, as well 
as ECE, an increase in dosage, and inclusion of long-term 
HT for five low-risk patients. Of these 45 patients, 22 
were allocated to the intermediate-risk group, resulting 
in the modification of the target volume due to the inclu-
sion of ECE and the addition of long-term HT. Lastly, the 
inclusion of ECE in the target volume was the only altera-
tion in 18 high-risk patients.
Of a total of five cT3a patients, one progressed to 
mT3b, but this case did not imply modifications of final 
RT treatment decisions, as in high-risk patients semi-
nal vesicles are always irradiated at full doses according 
to our institution’s protocol. Of the remaining four cT3a 
patients, three progressed to mT4 and consequently were 
treated with an increase in target volume to enable infil-
tration of the rectum or the bladder. Lastly, out of 127 
Table 1 Patients characteristics
mpMRI multiparametric magnetic resonance imaging, PSA prostate-specific 
antigen
Characteristics Total cohort (%) Radical  
prostatectomy (%)
Patients 274 (100) 90 (100)
Age (years) 66.8 ± 8.1 60.9 ± 6.8
PSA (ng/mL)
 <10 179 (65.3) 68 (75.6)
 10–20 66 (24.1) 18 (20.0)
 >20 29 (10.6) 4 (4.4)
Gleason score
 ≤6 137 (50.0) 60 (66.7)
 7 108 (39.4) 24 (26.7)
 ≥8 29 (10,6) 6 (6.6)
cT‑category before mpMRI
 ≤T2a 239 (87.2) 84 (93.3)
 T2b–T2c 30 (11.0) 6 (6.7)
 T3a 5 (1.8) 0
 T3b 0 0
 T4 0 0
Risk groups
 Low 95 (34.7) 43 (47.8)
 Intermediate 127 (46.4) 37 (41.1)
 High 52 (19.0) 10 (11.1)
Positive prostate biopsies
 <50 % 158 (57.7) 49 (54.4)
 ≥50 % 65 (23.7) 16 (17.8)
 (Non classified) 51 (18.6) 25 (27.8)
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intermediate-risk and 52 high-risk patients, stage IV was 
diagnosed in two and four patients respectively (3.4  %). 
In these patients, treatment consisted of either HT exclu-
sively, or pelvic RT and long-term HT.
In general, the mpMRI staging led to the identifica-
tion of more intermediate-risk and high-risk patients 
compared to conventional clinical staging. As a result, 
a higher occurrence of irradiation of seminal vesicles, 
inclusion of any ECE (T3–T4), and more frequent pre-
scription of combined RT/HT, as well as higher doses of 
RT (p < 0.05), were observed (Table 2).
In order to validate the mpMRI results, 90 patients 
treated with RP were analysed. The mT-category and 
the pT-category were compared (Table  3). Global accu-
racy of cT-staging with DRE/TRUS was 8.9  % (8/90), 
while it was 71.1  % (64/90) for mpMRI. Among the 
51 patients upstaged from cT1–T2a to mT2b–T2c, 38 
patients (74.5 %) showed MRI findings in agreement with 
the pathological staging. For the 12 patients upstaged 
from cT1–T2 to mT3, this agreement occurred in seven 
patients (58.3 %). This entailed a 91.1 % accuracy, 70.0 % 
(95  % CI 41.6–98.4) sensitivity, 93.8  % (95  % CI 88.5–
99.1) specificity, 58.3 % positive predictive value (95 % CI 
30.4–86.2) and a 96.2  % negative predictive value (95  % 
CI 91.9–100) in the MRI staging of ECE (T3) patients.
Having the pT-staging as the gold standard, there was 
less disagreement in the RT treatment decisions (CTV, 
HT indication, RT prescription dose) with mT-staging 
compared to cT-staging (Table 3).
Clinical factors associated to mpMRI reliability
Possible clinical variables associated with an increase in 
mpMRI reliability were analysed in relation to tumour 
staging through univariate and multivariate logistic 
regression analysis. None of the clinical factors analysed 
(PSA value, GS,   % ppb and age) showed a significant 
association with mpMRI reliability (Table 4).
Discussion
We believe that this is the largest cohort of patients in 
which the impact of mpMRI staging on RT treatment 
has been analysed. In brief, 90.9  % of patients showed 
tumour upstaging as a result of mpMRI. Nevertheless, 
when considering all the risk factors together, such as 
PSA levels, GS, and tumour category, a change in the 
risk groups occurred in only 32.8  % of patients. In our 







T1a 0 0 0 0 0 0 0 0 0 0 0
T1b 0 1 1 1 3 1 1 0 0 7 1
T1c 0 0 2 50 22 89 14 13 1 189 2
T2a 0 0 0 12 4 18 4 1 1 28 12
T2b 0 0 0 0 5 11 0 4 2 17 5
T2c 0 0 0 0 0 4 0 3 1 4 4
T3a 0 0 0 0 0 0 1 1 3 4 1
T3b 0 0 0 0 0 0 0 0 0 0 0







Fig. 1 Comparison between cT and mT‑staging. The panel shows in 
bold black, those patients whose clinical stage was similar using both 
strategies
Table 2 Impact of  mpMRI tumor staging on  RT treatment 
prescription (target volume, doses and hormonal therapy)
VVSS seminal vesicles, DRE/TRUS digital rectal exam/transrectal ultrasound
a Initial criteria: GS of 7 (4 + 3), or three unfavourable IR factors (T2b + PSA 
10-20 ng/mL + GS 3 + 4), or T2c by DRE/TRUS
b MSKCC criteria: GS 4 + 3, or at least two IR factors, or at least one IR factor and 
a positive prostate biopsy (ppb) percentage greater than 50 %
Characteristics DRE/TRUS n (%) mpMRI n (%) p value
T-category
T1–T2a 239 (87.2) 67 (24.5) <0.001
T2b–T2c 30 (11.0) 157 (57.3)
T3–T4 5 (1.8) 50 (18.2)
Risk group
Low‑risk (LR) 95 (34.7) 32 (11.7) <0.001
Intermediate‑risk (IR) 127 (46.4) 163 (59.5)
High‑risk (HR) 52 (19.0) 79 (28.8)
Target volume
VVSS prophylactic 174 (63.5) 192 (70.1) <0.001
T3a + T3b + T4 5 (1.8) 50 (18.2)
Doses
Low 95 (34.7) 32 (11.7) <0.001
High 179 (65.3) 242 (88.3)
Hormonal therapy
HR and IR (Initial criteria)a
 No 182 (66.4) 158 (57.7) 0.035
 Yes 92 (33.6) 116 (42.3)
HR and IR (MSKCC criteria)b
 No 149 (54.4) 103 (37.6) <0.001
 Yes 125 (45.6) 171 (62.4)
Hormonal therapy in IR patients
Initial criteria
 No 220 (80.3) 221 (80.7) 0.914
 Yes 54 (19.7) 53 (19.3)
MSKCC criteria 0.002
 No 180 (65.7) 144 (52.6)
 Yes 94 (34.3) 130 (47.4)
Hormonal therapy in HR patients
No 222 (81.0) 195 (71.2) 0.007
Yes 52 (19.0) 79 (28.8)
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patient series, upstaging derived from mpMRI modi-
fied RT treatment for three main reasons: alteration of 
a patient’s risk group; extension of target volume due to 
any type of ECE (T3–T4 patients) in high-risk patients; 
or treatment with short-term HT due to accumulation 
of unfavourable factors in intermediate-risk patients. 
While there are proven benefits in overall survival (OS) 
among high-risk patients of long-term HT associated 
with high-dose RT (Zapatero et al. 2015), these benefits 
are not clear in all intermediate-risk patients (D’Amico 
2015). With the available scientific evidence on the mat-
ter, many authors recommend associating HT with 
high-dose RT only in intermediate-risk patients with 
unfavourable factors (D’Amico 2015), and this is the pro-
tocol we have applied at our institution.
Very few studies have evaluated the impact of MRI 
staging on final decisions in RT treatment (Table 5). We 
obtained a global alteration of RT treatment in 43.8 or 
52.5 % of patients (depending on HT criteria for interme-
diate-risk patients). Other studies have shown a change in 
RT treatment of between 8 and 34 %. Such variability can 
be due to several causes: some studies included patients 
who underwent MRI after starting HT treatment, lead-
ing to a reduction of tumour size and consequently a false 
downstaging (Panje et al. 2015; Chang et al. 2014); on the 
other hand, most of the studies in this context were per-
formed using 1.5T MRI without endorectal coil (Panje 
et  al. 2015; Yamaguchi et  al. 2015; Chang et  al. 2014; 
Jackson et  al. 2005) whereas our investigation was con-
ducted using 3T MRI, with higher diagnostic reliability 
(Park et al. 2007). Morphological MRI has been used in 
most of the reported series without functional associ-
ated studies (Horsley et al. 2015; Yamaguchi et al. 2015; 
Chang et al. 2014; Jackson et al. 2005). Our study imple-
mented the guide-recommended (Barentsz et  al. 2012) 
morphological T2 sequences along with two functional 
studies (DWI and DCE), increasing the diagnosis rate, as 
previously reported (Wu et al. 2012; Verma et al. 2012). 
In particular, we observed a large number of patients ini-
tially categorized as cT1–T2a (239 patients), which might 
have contributed to such a marked degree of upstaging. 
On the other hand, in many of the aforementioned stud-
ies, HT was administered to all intermediate-risk patients 
(Panje et  al. 2015; Horsley et  al. 2015; Yamaguchi et  al. 
2015; Chang et al. 2014; Jackson et al. 2005), independ-
ent of unfavourable risk factors. In this respect, if we had 
considered administering HT to all intermediate-risk 
Table 3 mT-staging validation for the indication of RT treatment
For patients whose final treatment consisted of RP (n = 90), the cT-and mT-category were compared to the pathologic tumour stage (pT-category), which allowed us 
to validate DRE/TRUS and mpMRI results. Furthermore, the analysis and comparisons related to RT treatment decisions were done for DRE/TRUS vs. mpMRI
RT radiotherapy, HT hormonal therapy, CTV clinical target volume
DRE/TRUS n (%) mpMRI n (%) p value Prostatectomy piece n (%)
T-category
T1–T2a 84 (93.7) 24 (26.7) <0.001 23 (25.6)
T2b–T2c 6 (6.7) 54 (60.0) 57 (63.3)
T3–T4 0 12 (13.3) 10 (11.1)
Risk group
Low‑risk 43 (47.8) 13 (14.4) <0.001 10 (11.1)
Intermediate‑risk 37 (41.1) 59 (65.6) 65 (72.2)
High‑risk 10 (11.1) 18 (20.0) 15 (16.7)
Global reliability for T-category 8 (8.8) 64 (71.1) <0.001
Risk group change due to pathological analysis 37 (41.1) 15 (16.7) <0.001
Changes related to RT parameters (HT, Doses, CTV)
Initial criteria 45 (50.0) 16 (17.8) <0.001
MSKCC criteria 59 (65.6) 18 (20.0)
Table 4 Multivariate analysis of clinical factors associated 
to mpMRI reliability
ppb positive prostate biopsies
a No significant differences were found when considering Gleason ≤6 and 
Gleason = 7 (3 + 4) compared to the rest of Gleason score. Similar lack of 
significant differences were observed when Gleason = 6 was compared to 
Gleason = 7 or Gleason = 8–10
OR 95 % CI p‑value
PSA <10 Reference
PSA 10–20 0.43 (0.03–5.05) 0.50
PSA >20 0.61 (0.04–8.21) 0.70
Gleason ≤6a Reference
Gleason ≥7 1.39 (0.41–4.65) 0.58
ppb <50 % Reference
ppb ≥50 % 1.07 (0.31–3.69) 0.90
Age 0.92 (0.84–1.00) 0.06
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patients, the impact of RT treatment would have 
decreased to 41.2  %. On the other hand, in the litera-
ture, conventional clinical staging was performed not 
only using DRE/TRUS, but also with pelvic CT (Panje 
et al. 2015), which could have influenced the final results. 
Lastly, it must be remarked that patients who progressed 
to the metastatic category due to pelvic node involve-
ment and/or bone metastases were taken into account. In 
some studies, these patients were excluded from the final 
analysis (Horsley et al. 2015).
The greatest impact of mpMRI on RT treatment pre-
scription occurs in low-risk or intermediate-risk cT1–T2 
patients who progress to mT3–T4, due to the fact that in 
addition to expanding the target volume to include ECE, 
we must associate long-term HT with the increased tox-
icity this entails. Our study shows that 16.7 % of patients 
were upstaged to T3–T4. This result is similar to that 
found by Horsley et  al.(2015), who investigated the 
impact on RT treatment prescription of staging using 
morphological 1.5 T MRI with body-coil. In their study 
of 509 patients, Horsley et al. found that 20 % of patients 
initially categorized as T1–T2 were upstaged to T3–T4 
based on MRI findings. On the other hand, Jackson et al. 
(2005) obtained a 35.2  % change in treatment decision 
due to MRI findings in T3–T4 patients. This value can 
be seen as unrealistic, given the fact that in our surgical 
patient cohort, mpMRI testing showed a low predictive 
positive value (58.3  %) for T3 staging; this potentially 
constitutes an over-diagnosis, and consequent over-treat-
ment and increased toxicity in patients. These data are 
consistent with a recent meta-analysis that warns of the 
low sensitivity of MRI in ECE detection (de Rooij et  al. 
2015). However, a limited number of patients would be 
under-treated due to the high negative predictive value 
(96.2 %) for any ECE detection. In contrast, we obtained 
71.0  % for overall accuracy with mpMRI staging, while 
the value for DRE/TRUS was only 8.8  %. Globally, mT 
staging allowed us to prescribe RT treatments with 
higher reliability than did cT-staging.
In our series, the global change within the patient risk 
group was analysed considering the tumour category, as 
well as the PSA level and the GS. Ours results are compa-
rable to a recent paper published by Panje et al. (32.8 vs 
28.7 %) (Panje et al. 2015). These data suggest that a mini-
mum of approximately 30  % of prostate cancer patients 
staged with mpMRI could face an alteration of the final 
RT treatment decision. The ultimate impact on treatment 
prescription will vary according to the different care pro-
tocols in prostate cancer management, such as the cri-
teria to include the seminal vesicles or pelvis within the 
target volume, administered treatment doses, HT criteria 
in intermediate-risk patients, and the use of combined 
brachytherapy with RT. Unfortunately, all these issues are 
very variable among different institutions (Horsley et al. 
2015).
When analysing which patients would benefit most 
from undergoing MRI for staging purposes, our study, 
along with those of Panje and Horsley (Panje et al. 2015; 
Horsley et al. 2015), found significant upstaging in all risk 
groups—in our case, 86–94 % for any PSA or GS value. 
In addition, we observed that 66.3 % of low-risk patients 
progressed to intermediate-risk or high-risk; 18.1  % of 
intermediate-risk patients progressed to high-risk or 
metastatic; and 7.7 % of high-risk patients were upstaged 
to metastatic. Also, of the 45 patients upstaged to T3–T4 
because of mT-staging, 11.1, 48.9 and 40.0  % were ini-
tially low-risk, intermediate-risk, and high-risk, respec-
tively. Lastly, though there are published studies that 
Table 5 Clinical studies evaluating the impact of the staging using MRI in PCa patients treated with RT
Not RT change reported
PAB Phased-array-bodycoil, NR not reported, CTV clinical target volume, HT hormonal therapy
a Exclusive assessment of the CTV change
b Data from T1–T2 to T3–T4 upstaging
c Values according to the HT criteria in intermediate-risk patients
Study Type of MRI n Field 
strength









Panje et al. (2015) Multiparametric 122 1.5 T & 3 T PAB 55.7 28.7 30 No
Horsley et al. (2015) Morphological 509 1.5 T PAB 20 9 18 No
Yamaguchi et al. 
(2015)
Morphological 157 1.5 T PAB 25 9 8a No
Couñago et al. (2014) Multiparametric 103 3 T PAB 94.1 33.9 33.9 Yes
Chang et al. (2014) Morphological 115 1.5 T PAB 68.6 7 20a No
Jackson et al. (2005) Morphological 199 1.5 T PAB 55 NR 32.6b No
Present study Multiparametric 274 3 T PAB 90.4 32.8 43.8 or 52.5c Yes
Page 7 of 8Couñago et al. SpringerPlus  (2015) 4:789 
suggest that tumour detection and location are worse 
the lower the GS value and tumour size are (Bratan et al. 
2013), our univariant and multivariant logistic regression 
analysis showed no clinical factors associated with lower 
technique reliability in tumour staging. Consequently, in 
our clinical environment, all patients with localised pros-
tate cancer who are being considered for RT will benefit 
from mpMRI staging.
This study presents the following limitations: first, it 
is a retrospective study with all the inherent limitations 
associated with this design; second, our follow-up time 
was not long enough to validate the prognostic signifi-
cance of upstaging through mpMRI, although this was 
not the main aim of the study; third, as mpMRI is more 
accurate than DRE/TRUS and led to a change in T-cate-
gory or management, this did not lead to increased sur-
vival in patients. This hypothesis should be confirmed 
in a phase three clinical trial; fourth, the radiologist was 
not blinded, and consequently knew the patients’ initial 
clinical category before the MRI took place. This bias 
was minimised when quantitative parameters such as 
ADC or semi-quantitative ones such as time-intensity 
curves were analysed. In addition, this is common clini-
cal practice and is assumed in most published studies on 
this matter (Panje et al. 2015; Horsley et al. 2015; Yama-
guchi et al. 2015; Chang et al. 2014; Jackson et al. 2005). 
Lastly, DRE/TRUS reliability was found to be very low 
in our study (8.8 %), and this could have influenced the 
elevated upstaging values observed with mpMRI. Having 
said this, the literature on this subject describes very low 
reliability for DRE/TRUS in tumour staging (<50 %), and 
high interobserver variability (Philip et  al. 2005; Smith 
and Catalona 1995). However, the impact of upstaging 
on risk-group modification (according to all factors—T-
staging, PSA and GS) was similar to other study using 
mpMRI (Panje et al. 2015).
In conclusion, mpMRI tumour staging significantly 
modified the RT treatment decisions in all prostate can-
cer risk groups. Approximately 30  % of patients may 
experience a change in their initial risk group based on 
mpMRI findings. The magnitude of the impact on final 
RT treatment decisions will depend on the institution’s 
clinical protocol for prostate cancer management.
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